Last reviewed · How we verify
SafeTynadol®
SafeTynadol® is a modified formulation of acetaminophen designed to reduce hepatotoxicity risk through enhanced safety mechanisms.
SafeTynadol® is a modified formulation of acetaminophen designed to reduce hepatotoxicity risk through enhanced safety mechanisms. Used for Pain relief and fever reduction (marketed indication presumed).
At a glance
| Generic name | SafeTynadol® |
|---|---|
| Also known as | SNP-810, Placebo B + Tween20 and PEG400 |
| Sponsor | Sinew Pharma Inc. |
| Drug class | Analgesic/antipyretic (acetaminophen derivative) |
| Target | Presumed COX inhibitor and TRPV1 modulator (acetaminophen mechanism) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Fever |
| Phase | FDA-approved |
Mechanism of action
SafeTynadol® appears to be a branded acetaminophen product marketed with safety enhancements, likely involving modified-release technology or formulation adjustments to minimize peak plasma concentrations and reduce the risk of liver injury. The product name suggests a focus on safer dosing or metabolism compared to standard acetaminophen formulations.
Approved indications
- Pain relief and fever reduction (marketed indication presumed)
Common side effects
- Hepatotoxicity
- Nausea
- Rash
Key clinical trials
- A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers (NA)
- A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SafeTynadol® CI brief — competitive landscape report
- SafeTynadol® updates RSS · CI watch RSS
- Sinew Pharma Inc. portfolio CI